Scientific researchers now have advanced options for developing non-immunoglobulin G (non-IgG) antibodies, thanks to Creative Biolabs' sophisticated production methodologies targeting IgE, IgM, and IgA antibodies. The company's proprietary technologies are poised to accelerate immunotherapy research and development across multiple medical disciplines.
Focusing on three distinct antibody types, Creative Biolabs has developed specialized techniques addressing unique challenges in antibody production. For IgE antibodies, the company has optimized expression systems using CHO and HEK293 cells, ensuring high expression levels and stability. Their approach overcomes traditional purification challenges through advanced strategies like affinity and ion exchange chromatography.
IgM antibodies, crucial in primary immune responses, present unique production complexities due to their large molecular weight. The company has developed multiple purification methods, including three-step and two-step techniques that balance high recovery rates with exceptional product purity. These methods enable researchers to obtain IgM antibodies meeting rigorous preclinical study standards.
The company's work with IgA antibodies highlights emerging opportunities in mucosal immunity research. By developing both monomeric and dimeric IgA from diverse cell expression systems, Creative Biolabs supports fundamental studies and potential medicinal product development. Their peptide M affinity chromatography technique stands out for its high selectivity and capacity to produce substantial quantities of purified IgA.
These advancements represent significant progress in non-IgG antibody research, potentially accelerating innovations in treating complex medical conditions including cancer, infectious diseases, and inflammatory disorders. By providing scalable, high-quality antibody solutions, Creative Biolabs is positioning itself at the forefront of immunotherapy research and development.
